Brain Markers and Recovery of Language After Stroke
Studies brain and gene markers of language recovery in adults with aphasia after stroke.
Plain-language title generated from the registry record
Registry title: Neuroplasticity Biomarkers in Aphasia
Key facts
- Where
- Madison, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 90 years old?
Source: NCT06471127, who can take part
Where in United States
- UW School of Medicine and Public HealthMadison, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Wisconsin, Madison
- Trial code
- NCT06471127
- Record updated
- 7 July 2026
- Original description
Patients with stroke frequently suffer from aphasia, a disorder of expressive and/or receptive language, that can lead to serious health consequences, including social isolation, depression, reduced quality of life, and increased caregiver burden. Aphasia recovery varies greatly between individuals, and likely relies upon the capacity for neuroplasticity, both at a systems level of reorganized brain networks and a molecular level of neuronal repair and plasticity. The proposed work will evaluate genetic and neural network biological markers of neuroplasticity associated with variability in aphasia, with a future goal to improve prognostics and identify therapeutic targets to reduce the long-term burdens of aphasia.Read full original descriptionShow less
Genetic and MRI Biomarkers of Neuroplasticity Predict Aphasia Recovery and Phenotypes
Patients with stroke frequently suffer from aphasia, a disorder of expressive and/or receptive language, that can lead to serious health consequences, including social isolation, depression, reduced quality of life, and increased caregiver burden. Aphasia recovery varies greatly between individuals, and likely relies upon the capacity for neuroplasticity, both at a systems level of reorganized brain networks and a molecular level of neuronal repair and plasticity. The proposed work will evaluate genetic and neural network biological markers of neuroplasticity associated with variability in aphasia, with a future goal to improve prognostics and identify therapeutic targets to reduce the long-term burdens of aphasia.
Inclusion: Ages 40-90; Right-handed (prior to stroke); Proficient English speakers; History of a single ischemic stroke in the middle cerebral artery territory that is lateralized to the left or right (Aim 1) cerebral hemisphere; Presence of aphasia (Aims 2-3); Capacity to understand the nature of the study and provide informed consent; Acute or subacute stroke at the time of Aim 1 enrollment; Stroke #12 months old (chronic) at the time of Aims 2-3 enrollment; Medically stable.
Exclusion: Current abuse of alcohol or drugs, prescription or otherwise; History of significant medical or neurological disorder (other than stroke); History of significant or poorly controlled psychiatric disorders; Anything other than standard of care stroke treatment such as Plavix, aspirin (81-300 mg daily), beta-blockers, diabetes medications or choles- terol-lowering agents, thrombolytics (e.g., tPA), anticoagulation agents such as Heparin, Warfarin/Coumadin; Clinically significant and uncorrected vision or hearing loss.